Follow
Pengfei Yu
Pengfei Yu
Verified email at pennmedicine.upenn.edu
Title
Cited by
Cited by
Year
New horizons in tumor microenvironment biology: challenges and opportunities
F Chen, X Zhuang, L Lin, P Yu, Y Wang, Y Shi, G Hu, Y Sun
BMC medicine 13, 1-14, 2015
7382015
Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species
J Su, X Chen, Y Huang, W Li, J Li, K Cao, G Cao, L Zhang, F Li, ...
Cell Death & Differentiation 21 (3), 388-396, 2014
2592014
TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2+ neutrophils
PF Yu, Y Huang, YY Han, LY Lin, WH Sun, AB Rabson, Y Wang, YF Shi
Oncogene 36 (4), 482-490, 2017
2202017
TGF-β promotes immune responses in the presence of mesenchymal stem cells
C Xu, P Yu, X Han, L Du, J Gan, Y Wang, Y Shi
The Journal of Immunology 192 (1), 103-109, 2014
1352014
An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles
A Ortiz, J Gui, F Zahedi, P Yu, C Cho, S Bhattacharya, CJ Carbone, Q Yu, ...
Cancer cell 35 (1), 33-45. e6, 2019
1322019
miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2
C Xu, G Ren, G Cao, Q Chen, P Shou, C Zheng, L Du, X Han, M Jiang, ...
Journal of Biological Chemistry 288 (16), 11074-11079, 2013
1032013
Downregulation of CXCL12 in mesenchymal stromal cells by TGFβ promotes breast cancer metastasis
PF Yu, Y Huang, CL Xu, LY Lin, YY Han, WH Sun, GH Hu, AB Rabson, ...
Oncogene 36 (6), 840-849, 2017
802017
Tumour cell-derived exosomes endow mesenchymal stromal cells with tumour-promotion capabilities
LY Lin, LM Du, K Cao, Y Huang, PF Yu, LY Zhang, FY Li, Y Wang, YF Shi
Oncogene 35 (46), 6038-6042, 2016
802016
p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation
Y Huang, P Yu, W Li, G Ren, AI Roberts, W Cao, X Zhang, J Su, X Chen, ...
Oncogene 33 (29), 3830-3838, 2014
712014
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
ES Lightcap, P Yu, S Grossman, K Song, M Khattar, K Xega, X He, ...
Science translational medicine 13 (611), eaba7791, 2021
552021
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors
H Zhang, P Yu, VS Tomar, X Chen, MJ Atherton, Z Lu, HG Zhang, S Li, ...
Nature cancer 3 (7), 808-820, 2022
252022
Regulation of intercellular biomolecule transfer–driven tumor angiogenesis and responses to anticancer therapies
Z Lu, A Ortiz, II Verginadis, AR Peck, F Zahedi, C Cho, P Yu, RM DeRita, ...
The Journal of Clinical Investigation 131 (10), 2021
142021
Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers
O Odnokoz, P Yu, AR Peck, Y Sun, AJ Kovatich, JA Hooke, H Hu, ...
Cancer biology & therapy 21 (7), 629-636, 2020
102020
Tumor-suppressive and immune-stimulating roles of cholesterol 25-hydroxylase in pancreatic cancer cells
N McBrearty, C Cho, J Chen, F Zahedi, AR Peck, E Radaelli, ...
Molecular Cancer Research 21 (3), 228-239, 2023
72023
Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer
Z Lu, J Chen, P Yu, MJ Atherton, J Gui, VS Tomar, JD Middleton, ...
Nature communications 13 (1), 6623, 2022
72022
RALDH1 inhibition shows immunotherapeutic efficacy in hepatocellular carcinoma
P Yu, S Cao, SM Yang, G Rai, NJ Martinez, A Yasgar, AV Zakharov, ...
Cancer Immunology Research 12 (2), 180-194, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–16